Fig. 5.

In vivo recovery of CMV-specific immunity in patients after CMV-CTL therapy. A Patients received donor CMV-CTLs, and B patients received third-party CMV-CTLs. Lines represent counts of lymphocytes, CD3⁺CD8⁺ T cells, tetramer⁺ T cells and CMV viral load. C TCR CDR3 spectratyping of CMV-CTLs sorted from the infusion lines and PBMC samples from two third-party CMV-CTL-infused patients. The TCR clonotype was defined based on clonotypes with the same CDR3 amino acid (CDR3aa) sequence plus the Vβ and Jβ genes. Each circle represents a clonotype. The diameter of the circle indicates the concentration of the clonotype. Clonotypes that persisted in the infused CMV-CTL lines or in PBMCs pre-CMV-CTL infusion (at Day 0) are marked as colorful and bright circles, and a single color represents one clonotype. Emerging clonotypes are uniformly marked as gray circles. Patients in Fig. 5 all received CMV-seropositive allografts